Double-barrelled name

Earnin Strengthens Team with Heavy Hitting Legal Lineup

Retrieved on: 
Wednesday, December 7, 2022

In his role, Durant will oversee all aspects of Earnins legal, regulatory, and government relations matters, with dos Santos serving as his chief deputy.

Key Points: 
  • In his role, Durant will oversee all aspects of Earnins legal, regulatory, and government relations matters, with dos Santos serving as his chief deputy.
  • The experience David and Simone bring to Earnin aligns with our customer-first approach to offer financial well-being products that empower our users, said Ram Palaniappan, Founder and CEO of Earnin.
  • Through these additions to the legal team, Earnin will strengthen our ability to create safe and consumer-friendly products that shift the fabric of our financial system for the betterment of workers.
  • As of September 2021, Earnin has performed more than 125 million transactions and provided access to $10 billion in earnings for its members.

FutureProof Augments Team to Bring Fresh Approach to Risk Starting with Florida Homeowners Insurance

Retrieved on: 
Wednesday, October 26, 2022

FutureProof Technologies has announced two key hires to support the launch of a Florida E&S homeowners product through its algorithmic underwriting MGA.

Key Points: 
  • FutureProof Technologies has announced two key hires to support the launch of a Florida E&S homeowners product through its algorithmic underwriting MGA.
  • FutureProofs API delivers quotes to wholesale brokers instantly based on its innovative view of risk, beginning in the Florida homeowners insurance market.
  • Norton commented, The insurance crisis in Florida, coupled with impacts from Hurricane Ian, underscore the urgent need for a sharper view of risk.
  • The Florida insurance crisis is not just about climate risk, but also about factors such as unmodeled social inflation and litigation costs.

Illumina to Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022

Retrieved on: 
Monday, October 17, 2022

SAN DIEGO, Oct. 17, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022.

Key Points: 
  • SAN DIEGO, Oct. 17, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022.
  • The webcast will begin at 9:30 am Pacific Time (12:30 pm Eastern Time) on Friday, October 28, 2022.
  • Interested parties may register and access the event through the Investor Info section of Illumina's website at investor.illumina.com or directly at Illumina Virtual ESG Investor Event .
  • A replay of the webcast will be posted on Illumina'swebsite after the event and will be available for at least 30 days following.

Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum

Retrieved on: 
Thursday, September 29, 2022

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced multiple breakthrough sequencing innovations at its inaugural Illumina Genomics Forum:

Key Points: 
  • Illumina Complete Long-Reads, formerly known as Infinity, will accelerate access to the remaining 5% of genic regions with a scalable, high-throughput, low DNA-input long read technology.
  • Further, the technology provides a complete and accurate representation of the genome at the single molecule level without needing a new platform.
  • These announcements came on the second day of the inaugural Illumina Genomics Forum, which runs through October 1.For more information, please visit illuminagenomicsforum.com .
  • Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets.

Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Retrieved on: 
Thursday, September 29, 2022

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives.

Key Points: 
  • With its NovaSeq X Series, Illumina redesigned every dimension of its world-class sequencers to further increase speed, scale, accuracy, and sustainability.
  • NovaSeq X also significantly reduces waste and environmental impact, reflecting Illumina's commitment to using its technology to support the health of people and the planet.
  • NovaSeq X features a 90% reduction in packaging waste and weight and 50% reduction in plastic usage compared to NovaSeq 6000.
  • "I strongly believe NovaSeq X Series will accelerate our path towards the $100 genome.

Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Retrieved on: 
Thursday, September 29, 2022

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives.

Key Points: 
  • With its NovaSeq X Series, Illumina redesigned every dimension of its world-class sequencers to further increase speed, scale, accuracy, and sustainability.
  • NovaSeq X also significantly reduces waste and environmental impact, reflecting Illumina's commitment to using its technology to support the health of people and the planet.
  • NovaSeq X features a 90% reduction in packaging waste and weight and 50% reduction in plastic usage compared to NovaSeq 6000.
  • "I strongly believe NovaSeq X Series will accelerate our path towards the $100 genome.

llumina Announces Opportunity to View Live Webcast of Illumina Genomics Forum Innovation Roadmap Session Followed by Investor Conference Call

Retrieved on: 
Thursday, September 8, 2022

SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that investors, analysts, and other interested parties may view a live webcast of the Innovation Roadmap session of the Illumina Genomics Forum, which will be hosted by Francis deSouza, Chief Executive Officer, and Alex Aravanis, Chief Technology Officer.

Key Points: 
  • SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that investors, analysts, and other interested parties may view a live webcast of the Innovation Roadmap session of the Illumina Genomics Forum, which will be hosted by Francis deSouza, Chief Executive Officer, and Alex Aravanis, Chief Technology Officer.
  • The session will be held from 9:00-10:00am Pacific Time (12:00-1:00pm Eastern Time), Thursday, Sept. 29, 2022.
  • Interested parties may access the live webcast of the Innovation Roadmap session of the Illumina Genomics Forum through the Investor Info section of Illumina's website at investor.illumina.com .
  • Individuals may access the live investor conference call with Illumina management through the same page or, alternatively, by dialing 866.409.1555 or +1.313.209.4906 outside North America, both with Conference ID 7572314.

Illumina Genomics Forum to Feature Diverse Lineup of Visionary Global Leaders

Retrieved on: 
Wednesday, September 7, 2022

SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of the full agenda for its inaugural Illumina Genomics Forum. The agenda for the four-day event can be seen here.

Key Points: 
  • SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of the full agenda for its inaugural Illumina Genomics Forum.
  • The forum will feature over 70 speakers and panelists, spanning leaders from translational and clinical research organizations, government institutes, and academia, as well as hospital leadership, clinicians, payers, and patient advocates.
  • This speaker lineup includes former President Barack Obama, Bill Gates, 23andMe co-founder and CEO Anne Wojcicki, tennis legend and cancer survivor Chris Evert, and American Cancer Society CEO Karen Knudsen, among other visionary leaders in health care and genomics.
  • Illumina Genomics Forum will take place in San Diego from September 28 through October 1.

Administrative Law Judge Rules in Favor of Illumina in FTC Challenge of GRAIL Deal

Retrieved on: 
Thursday, September 1, 2022

WASHINGTON, Sept.1, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), today received a favorable decision from the Administrative Law Judge (ALJ) presiding over the Federal Trade Commission's (FTC) challenge of the GRAIL acquisition.

Key Points: 
  • WASHINGTON, Sept.1, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), today received a favorable decision from the Administrative Law Judge (ALJ) presiding over the Federal Trade Commission's (FTC) challenge of the GRAIL acquisition.
  • "Reuniting Illumina and GRAIL will transform the detection and treatment of cancer by facilitating widespread, affordable access to GRAIL's life-saving Galleri test.
  • This decision is a step toward making that vision a reality," said Francis deSouza, Chief Executive Officer of Illumina.
  • GRAIL was founded by Illumina seven years ago with the goal of developing an early screening test for multiple types of cancer.

A New Orlando Advertising Agency With a Nontraditional Business Model is Launched by Industry Veteran Wagner dos Santos

Retrieved on: 
Tuesday, July 26, 2022

ORLANDO, Fla., July 26, 2022 /PRNewswire/ -- WGNR is the newest advertising and marketing agency founded by president and industry veteran, Wagner dos Santos. Agency operations commenced in June of this year following the closing of dos Santos' former agency, The Wagner Agency. After nearly six years of servicing global and national clients and receiving numerous awards, dos Santos felt it was time to wind down that agency in order to introduce a new advertising agency concept under a different entity and name.

Key Points: 
  • ORLANDO, Fla., July 26, 2022 /PRNewswire/ -- WGNR is the newest advertising and marketing agency founded by president and industry veteran, Wagner dos Santos.
  • Agency operations commenced in June of this year following the closing of dos Santos' former agency, The Wagner Agency.
  • The COVID-19 pandemic had a major impact on how rapidly this business model has taken off and continues to grow.
  • A recognized disrupter and maverick in the advertising industry, dos Santos began planning the formation of a subscription-based advertising and marketing agency and WGNR was born.